Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is critical to take HIV medications, particularly protease inhibitors, exactly as prescribed to reduce the risks of developing resistance. The Food and Drug Administration (FDA) recently approved a new drug, Combivir, a combination of 3TC (lamivudine) and AZT in one tablet. Combivir works by interfering with the HIV life cycle to prevent it from replicating, and is taken twice a day with or without food. Patients with low body mass, hepatitis, or liver or kidney disease should not take Combivir. Blood counts need to be monitored regularly when taking this drug. Potential side effects include headache, nausea, fatigue, diarrhea, nasal congestion, or flu-like symptoms. A phone number is provided for more information on Combivir.
 ...
PMID:What you need to know about Combivir. 1136 67

Information on dosage, cost, side effects, and interactions is provided for each of the seven nucleoside analog drugs available currently: Retrovir (AZT, ZDV), Videx (ddI), Hivid (ddC), Zerit (d4T), Epivir (3TC), Combivir (AZT/3TC), and Ziagen (abacavir sulfate). Most nucleoside analogs (with the exception of ddI) do not have food restrictions, but do have potential side effects such as nausea and fatigue. An activist, a doctor, and the drug's manufacturer offer comments. Contact information is provided.
 ...
PMID:What they say about nucleoside drugs. 1136 20

We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation.
 ...
PMID:Could antiretrovirals be treating EBV in MS? A case report. 2951 Mar 25